Research into the relationship between SARS-CoV-2 infection and amyotrophic lateral sclerosis has uncovered several plausible biological pathways by which the virus could contribute to motor neuron damage, though population-level evidence has not yet confirmed an increase in ALS diagnoses since the pandemic began. The picture that has emerged is complicated: laboratory studies show the virus can infect motor neurons and trigger protein changes associated with ALS, while epidemiological data from some regions actually shows a slight dip in recorded incidence during the pandemic years. What follows is a closer look at what researchers have found so far, what it means for people living with ALS, and where the genuine risks lie.
Whether SARS-CoV-2 Can Directly Infect Motor Neurons
One of the first questions researchers needed to answer was whether the virus could reach and enter the nerve cells that ALS destroys. A study using human motor neurons grown from stem cells in the lab demonstrated for the first time that these cells are permissive to SARS-CoV-2, meaning the virus can get inside them, replicate, and release infectious particles back into the surrounding environment.1PubMed Central. Human motor neurons derived from induced pluripotent stem cells are susceptible to SARS-CoV-2 infection That finding matters because it establishes that motor neurons are not simply bystanders caught in a systemic inflammatory storm. The virus has a direct route in.
That said, a lab dish is not a human spinal cord. Whether the virus reaches motor neurons in living people, and in what numbers, remains an open question. The same researchers who demonstrated infectivity in culture noted that the neurological symptoms seen in COVID patients could stem from direct viral invasion, from collateral inflammatory damage, or from some combination of both.1PubMed Central. Human motor neurons derived from induced pluripotent stem cells are susceptible to SARS-CoV-2 infection This distinction between the virus doing the damage itself versus the immune response doing the damage in its wake is one of the central unresolved questions in the field.
The TDP-43 Problem
If there is one protein that sits at the crossroads of COVID and ALS biology, it is TDP-43. In healthy cells, TDP-43 lives mostly in the nucleus, where it helps manage RNA. In roughly 97% of ALS cases, TDP-43 is found misplaced, clumped together in the cytoplasm, and chemically modified in ways that make it toxic to motor neurons. This pattern of TDP-43 going wrong is considered a hallmark of the disease.
SARS-CoV-2 appears to accelerate exactly this kind of damage. Several viral proteins have been shown to trigger cleavage, clumping, and misplacement of TDP-43.2PubMed Central. The Role of TDP-43 in SARS-CoV-2-Related Neurodegenerative Changes The infection also promotes the formation of stress granules, which are temporary clusters of protein and RNA that cells assemble when under threat. Under normal conditions these granules dissolve once the stress passes. But SARS-CoV-2 infection can push TDP-43 into a more condensed state within these granules, disrupting the cell’s ability to manage its own RNA.2PubMed Central. The Role of TDP-43 in SARS-CoV-2-Related Neurodegenerative Changes
A deeper mechanistic analysis describes how persistent or repeated cellular stress can overwhelm the buffering systems that normally keep TDP-43 in a healthy, fluid state. When those buffers are overloaded, TDP-43 hardens into insoluble, chemically modified aggregates that persist even after the original stress is gone. The downstream result is the same signature seen in ALS: TDP-43 drains out of the nucleus, piles up in the cytoplasm, becomes hyperphosphorylated, and forms irreversible clumps.3Cell Death. Neurotropic viruses and the TDP-43 axis: Reframing sporadic ALS through a viral-proteinopathy lens The implication is striking: a severe enough viral infection could theoretically push TDP-43 past a tipping point in someone whose cells were already borderline vulnerable.
This does not mean that catching COVID causes ALS in the way a mutation causes a genetic disease. What the evidence suggests is more subtle: viral infection may lower the threshold at which TDP-43 pathology takes hold, potentially accelerating a process that might otherwise have taken years longer to become symptomatic, or tipping someone who was genetically predisposed but might never have developed clinical disease.
What the Population Data Actually Shows
If COVID were triggering a wave of new ALS cases, you would expect to see it in epidemiological data. So far, the numbers tell a different story. An eight-year population study in Central Italy compared ALS incidence before and during the pandemic and found no upward trend. In fact, after including the pandemic years 2020 and 2021 in the statistical model, the researchers observed a mean decrease in ALS incidence of about 6%.4PubMed. Incidence of amyotrophic lateral sclerosis before and during the COVID-19 pandemic: evidence from an 8-year population-based study in Central Italy based on healthcare utilization databases
That decrease is probably not protective. More likely explanations include delayed diagnoses during lockdowns, reduced access to neurologists, and disrupted healthcare utilization patterns. ALS typically takes months to diagnose under normal circumstances, requiring multiple specialist visits and extensive testing. When hospitals were overwhelmed with COVID patients and people were avoiding medical facilities, many neurological evaluations were postponed or missed entirely.
It is also worth noting the timescale problem. Neurodegenerative diseases develop over years, sometimes decades, before symptoms appear. Even if SARS-CoV-2 infection does contribute to ALS in some people, an uptick in diagnoses might not emerge until the late 2020s or later. Researchers have pointed out that studying the long-term neurological consequences of COVID will require sustained follow-up of large cohorts, and we are still early in that process.5PubMed Central. Amyotrophic Lateral Sclerosis in Long-COVID Scenario and the Therapeutic Potential of the Purinergic System in Neuromodulation
How COVID Affects People Already Living With ALS
For people who already have ALS, COVID-19 infection poses particular dangers. ALS progressively weakens the muscles used for breathing, meaning many patients already have compromised respiratory function before any infection enters the picture. A study of hospitalized ALS patients who contracted COVID-19 found that all developed pneumonia, and a third of them died from respiratory failure and related complications.6PubMed Central. Impact of COVID-19 Infection Among Hospitalized Amyotrophic Lateral Sclerosis Patients That mortality rate, while based on a small sample, aligns with what clinicians would expect: a respiratory virus hitting lungs already weakened by progressive motor neuron loss is an especially dangerous combination.
The pandemic’s broader impact on ALS patients, however, was more about disrupted care than direct infection. A study in Valencia, Spain, tracked ALS patients across the pandemic divide and found no significant difference in survival between those who died before the pandemic and those who died during it, with median survival figures around 33 months in both groups. After adjusting for other variables, the pandemic had no statistically meaningful effect on overall ALS survival.7PubMed Central. Impact of SARS‐CoV‐2 infection and COVID‐19 pandemic on the morbidity and mortality of amyotrophic lateral sclerosis patients in Valencia, Spain This suggests that while individual COVID infections were dangerous for ALS patients, the pandemic as a systemic event did not dramatically alter the disease’s course at a population level, at least in settings where care networks adapted reasonably well.
A Shared Genetic Vulnerability
One of the more intriguing findings to emerge from pandemic-era research involves a gene called C9orf72. A large expansion in this gene is the most common known genetic cause of both ALS and frontotemporal dementia. The gene plays roles in immune function, cellular cleanup processes, and the trafficking of molecules within cells. People with C9orf72 expansions already tend to have elevated inflammatory markers and dysfunctional immune regulation.
Researchers investigated whether intermediate-length expansions in C9orf72, shorter than the full disease-causing mutation but longer than typical, might influence COVID severity. In a study of 240 patients with severe COVID-19 pneumonia, those carrying intermediate repeats of more than 10 units in at least one copy of the gene had roughly double the odds of needing ventilation compared to those with shorter expansions. That finding was validated in a separate group of 201 infected patients.8PubMed Central. C9orf72 Intermediate Repeats Confer Genetic Risk for Severe COVID-19 Pneumonia Independently of Age
This does not mean that ALS and severe COVID share a direct causal relationship. What it reveals is a shared biological territory: the same gene region implicated in motor neuron disease also appears to influence the immune response to SARS-CoV-2. For the small subset of people who carry these intermediate expansions, the virus may exploit a pre-existing weakness in the cell’s ability to regulate inflammation and clean up damaged proteins. Whether that shared vulnerability translates into a meaningful increase in future neurodegeneration risk remains unknown.
Neuroinflammation, Mitochondria, and the Long COVID Connection
Beyond direct motor neuron infection and TDP-43 damage, several broader biological disruptions in long COVID overlap with mechanisms known to contribute to ALS. Chronic neuroinflammation is at the top of the list. In ALS, overactive immune cells in the brain and spinal cord called microglia and astrocytes release inflammatory molecules that damage surrounding neurons. SARS-CoV-2 infection has been shown to accelerate this neuroinflammatory process in ways that may compound existing damage.5PubMed Central. Amyotrophic Lateral Sclerosis in Long-COVID Scenario and the Therapeutic Potential of the Purinergic System in Neuromodulation
Mitochondrial dysfunction has also emerged as a potential link. Motor neurons are among the most energy-hungry cells in the body, stretching enormous distances from the spinal cord to the extremities and relying on efficient mitochondrial function to keep working. Emerging evidence points to mitochondrial dysfunction as an underpinning mechanism contributing to the persistence and diversity of long COVID symptoms, including cellular energy deficits, oxidative stress, and immune dysregulation.9PubMed Central. Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches Motor neurons already operating near their bioenergetic limits would be disproportionately affected by any additional mitochondrial impairment.
Autoimmunity adds another layer of concern. Long COVID has been associated with the development of autoantibodies targeting brain tissue, and this brain-directed autoimmune activity has been linked to the fatigue, cognitive symptoms, and mood disturbances characteristic of the condition.10PubMed Central. Brain-targeted autoimmunity is strongly associated with Long COVID and its chronic fatigue syndrome as well as its affective symptoms While autoimmunity is not traditionally considered a primary driver of ALS, autoantibodies against neural tissue could contribute to a hostile environment for motor neurons that are already under stress from other factors.
Vaccination Considerations for ALS Patients
For people living with ALS, the question of COVID vaccination involves a tricky balance. The disease itself makes COVID infection more dangerous, as noted above, which argues strongly in favor of vaccination. But ALS patients also appear to experience more severe adverse events from vaccines generally. An analysis comparing vaccination-related adverse events across several neurodegenerative diseases found that ALS patients had the highest likelihood of severe reactions, a finding the researchers attributed to the known progression and systemic fragility of ALS rather than to any vaccine-specific mechanism.11Brain, Behavior, and Immunity – Health. Examining vaccination-related adverse events in frequent neurodegenerative diseases
The practical takeaway is not that ALS patients should avoid vaccination but that their care teams should be prepared for heightened monitoring around vaccination events. The risk of severe COVID-19 in someone with compromised respiratory muscles almost certainly outweighs the risk of vaccine-related adverse events, but the timing and management of vaccinations may need to be individualized, particularly for patients in more advanced stages of the disease.
Historical Echoes of Post-Viral Neurodegeneration
The concern that a pandemic virus could trigger a wave of neurological disease is not new. After the 1918 influenza pandemic, a mysterious condition called encephalitis lethargica appeared in large numbers. Patients developed profound sleepiness, movement disorders, and psychiatric symptoms, sometimes years after their original infection. The relationship between influenza and encephalitis lethargica was vigorously debated for years, with some researchers arguing for a direct causal link and others pointing to features of the condition that did not fit neatly with an influenza explanation.12PubMed Central. Encephalitis lethargica and the influenza virus. II. The influenza pandemic of 1918/19 and encephalitis lethargica: epidemiology and symptoms
A century later, that debate remains unresolved, which is itself instructive. Post-viral neurological conditions are real and have historical precedent, but proving that a specific virus caused a specific neurodegenerative outcome in a specific person is extraordinarily difficult. The latency between infection and symptom onset can span years. Multiple contributing factors, genetic susceptibility, environmental exposures, aging, may all be in play. And the neurological conditions that emerge after pandemics do not always behave the way the original viral disease did.
For COVID and ALS specifically, this history suggests patience will be required. If SARS-CoV-2 does contribute to motor neuron disease in some subset of infected individuals, the signal may not become clear for a decade or more. The biological mechanisms are plausible and increasingly well-described, but the epidemiological confirmation, or refutation, lies ahead.
Post-COVID Symptoms That Resemble ALS
One complication worth addressing is that long COVID itself can produce symptoms that superficially resemble early ALS. Muscle weakness, fatigue, fasciculations (visible muscle twitches), and difficulty with fine motor tasks have all been reported in long COVID patients. For someone aware of ALS as a possibility, these symptoms can be terrifying.
The critical difference is usually in the pattern and progression. ALS typically begins in one region of the body, a hand, a foot, the tongue, and spreads relentlessly over months. Reflexes tend to be abnormally brisk, and nerve conduction studies show a specific pattern of motor neuron loss. Long COVID symptoms, by contrast, tend to be more diffuse, fluctuating, and accompanied by fatigue and cognitive difficulties rather than the progressive, focal weakness characteristic of ALS. Neurologists evaluating post-COVID patients with motor complaints face the challenge of distinguishing true motor neuron disease from inflammatory or post-infectious mimics that may improve with time.
This is an area where the research community has stressed the importance of careful clinical evaluation rather than premature labeling.5PubMed Central. Amyotrophic Lateral Sclerosis in Long-COVID Scenario and the Therapeutic Potential of the Purinergic System in Neuromodulation Studying the pathophysiology behind ALS-like symptoms associated with SARS-CoV-2 infection has become a priority, both to identify people who truly are developing motor neuron disease and to reassure those whose symptoms, while real and distressing, have a more favorable trajectory.
Where the Research Stands on Therapeutic Overlap
The mechanistic overlap between COVID-related neurological damage and ALS pathology has opened up interest in whether treatments targeting shared pathways could benefit both conditions. Drugs that reduce neuroinflammation, stabilize TDP-43, or support mitochondrial function are under investigation for ALS and could theoretically also address some of the neurodegenerative consequences of severe COVID infection. The purinergic signaling system, which regulates neuroinflammation and immune responses in the brain, has been highlighted as one such potential therapeutic target.5PubMed Central. Amyotrophic Lateral Sclerosis in Long-COVID Scenario and the Therapeutic Potential of the Purinergic System in Neuromodulation
None of these avenues have produced approved treatments yet, and ALS has a long history of promising laboratory findings that fail to translate into clinical benefit. But the pandemic has injected new urgency and funding into neuroinflammation research broadly, and some ALS researchers view the increased scientific attention to post-viral neurodegeneration as an indirect benefit for their field. Understanding how a virus can push the nervous system toward disease may illuminate the underlying vulnerabilities that make some people develop ALS even without a viral trigger.